Economic impact of multiple sclerosis disease-modifying drugs in an employed population: direct and indirect costs*

Author： Birnbaum Howard G.   Ivanova Jasmina I.   Samuels Seth   Davis Matthew   Cremieux Pierre Y.   Phillips Amy L.   Meletiche Dennis  

Publisher： Informa Healthcare

ISSN： 1473-4877

Source： Current Medical Research and Opinion, Vol.25, Iss.4, 2009-04, pp. : 869-877

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Disease-modifying drugs in multiple sclerosis: a review of expenditure in Ireland

By Bailey B.  

Irish Journal of Medical Science, Vol. 180, Iss. 2, 2011-06 ,pp. : 337-341

Springer Publishing Company

Access to resources Recommend Favorite

Using observational analysis of multiple sclerosis relapse to design outcomes-based contracts for disease-modifying drugs: a feasibility assessment

By Lage Maureen J.   Carroll Cathryn A.   Fairman Kathleen A.  

Journal of Medical Economics, Vol. 16, Iss. 9, 2013-09 ,pp. : 1146-1153

Informa Healthcare

Access to resources Recommend Favorite

Managing adverse effects of disease-modifying agents used for treatment of multiple sclerosis

By Moses Harold   Brandes David W.  

Current Medical Research and Opinion, Vol. 24, Iss. 9, 2008-09 ,pp. : 2679-2690

Informa Healthcare

Access to resources Recommend Favorite

Disease‐modifying treatments for multiple sclerosis – a review of approved medications

By  

EUROPEAN JOURNAL OF NEUROLOGY, Vol. 23, Iss. S1, 2016-01 ,pp. : 18-27

John Wiley & Sons Inc

Access to resources Recommend Favorite

Persistence and adherence to disease modifying drugs among patients with multiple sclerosis

By Reynolds Matthew W.   Stephen Reejis   Seaman Chris   Rajagopalan Kitty  

Current Medical Research and Opinion, Vol. 26, Iss. 3, 2010-03 ,pp. : 663-674

Informa Healthcare

Access to resources Recommend Favorite